Literature DB >> 19258266

Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?

Maria Souli1, Panagiota Danai Rekatsina, Zoi Chryssouli, Irene Galani, Helen Giamarellou, Kyriaki Kanellakopoulou.   

Abstract

Using time-kill methodology, we investigated the interactions of an imipenem-colistin combination against 42 genetically distinct Klebsiella pneumoniae clinical isolates carrying a bla(VIM-1)-type gene. Irrespective of the imipenem MIC, the combination was synergistic (50%) or indifferent (50%) against colistin-susceptible strains, while it was antagonistic (55.6%) and rarely synergistic (11%) against non-colistin-susceptible strains (with synergy being observed only against strains with colistin MICs of 3 to 4 microg/ml). The combination showed improved bactericidal activity against isolates susceptible either to both agents or to colistin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19258266      PMCID: PMC2681524          DOI: 10.1128/AAC.01271-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals.

Authors:  Maria Souli; Flora V Kontopidou; Evangelos Koratzanis; Anastasia Antoniadou; Efthimia Giannitsioti; Pinelopi Evangelopoulou; Sofia Kannavaki; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Acquired metallo-beta-lactamases: an increasing clinical threat.

Authors:  Gian Maria Rossolini
Journal:  Clin Infect Dis       Date:  2005-10-31       Impact factor: 9.079

3.  Comparative in vitro killing of carbapenems and aztreonam against Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase.

Authors:  A Panagiotakopoulou; G L Daikos; V Miriagou; A Loli; E Tzelepi; L S Tzouvelekis
Journal:  Int J Antimicrob Agents       Date:  2007-01-12       Impact factor: 5.283

4.  Sources of diversity of carbapenem resistance levels in Klebsiella pneumoniae carrying blaVIM-1.

Authors:  A Loli; L S Tzouvelekis; E Tzelepi; A Carattoli; A C Vatopoulos; P T Tassios; V Miriagou
Journal:  J Antimicrob Chemother       Date:  2006-07-26       Impact factor: 5.790

Review 5.  Two decades of imipenem therapy.

Authors:  A C Rodloff; E J C Goldstein; A Torres
Journal:  J Antimicrob Chemother       Date:  2006-09-22       Impact factor: 5.790

6.  Characterization of a new integron containing bla(VIM-1) and aac(6')-IIc in an Enterobacter cloacae clinical isolate from Greece.

Authors:  Irene Galani; Maria Souli; Zoi Chryssouli; Konstantina Orlandou; Helen Giamarellou
Journal:  J Antimicrob Chemother       Date:  2005-03-10       Impact factor: 5.790

7.  Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.

Authors:  L Poirel; T Naas; D Nicolas; L Collet; S Bellais; J D Cavallo; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Activity of imipenem against VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model.

Authors:  G L Daikos; A Panagiotakopoulou; E Tzelepi; A Loli; L S Tzouvelekis; V Miriagou
Journal:  Clin Microbiol Infect       Date:  2007-02       Impact factor: 8.067

Review 9.  High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece--a review of the current evidence.

Authors:  A Vatopoulos
Journal:  Euro Surveill       Date:  2008-01-24

10.  Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.

Authors:  Jian Li; Kingsley Coulthard; Robert Milne; Roger L Nation; Steven Conway; Daniel Peckham; Christine Etherington; John Turnidge
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790

View more
  20 in total

1.  The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.

Authors:  Meredith G Jernigan; Ellen G Press; M Hong Nguyen; Cornelius J Clancy; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

2.  In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.

Authors:  Maria Souli; Irene Galani; Stefanos Boukovalas; Michael George Gourgoulis; Zoi Chryssouli; Kyriaki Kanellakopoulou; Theofano Panagea; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

Review 3.  Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.

Authors:  Phillip J Bergen; Zackery P Bulman; Sarith Saju; Juergen B Bulitta; Cornelia Landersdorfer; Alan Forrest; Jian Li; Roger L Nation; Brian T Tsuji
Journal:  Pharmacotherapy       Date:  2015-01       Impact factor: 4.705

4.  The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Zakuan Z Deris; Heidi H Yu; Kathryn Davis; Rachel L Soon; Jovan Jacob; Caron K Ku; Anima Poudyal; Phillip J Bergen; Brian T Tsuji; Jurgen B Bulitta; Alan Forrest; David L Paterson; Tony Velkov; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

Review 5.  Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria.

Authors:  Neelam Taneja; Harsimran Kaur
Journal:  Microbiol Insights       Date:  2016-03-20

6.  When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock.

Authors:  Håkan Hanberger; Christian G Giske; Helen Giamarellou
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

Review 7.  Carbapenems: past, present, and future.

Authors:  Krisztina M Papp-Wallace; Andrea Endimiani; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

Review 8.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 9.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 10.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.